GLAXOSMITHKLINE has confirmed it is currently experiencing an "ongoing supply constraint" of its Engerix-B (hepatitis B surface antigen recombinant (yeast) vaccine) adult in Australia, due to a precautionary halt in the manufacturing process.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 04 Aug 17
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Aug 17
